MOLN Molecular Partners

Life Science Cares Launches in Switzerland

Life Science Cares Launches in Switzerland

First international chapter of Life Science Cares established in Switzerland – bringing hearts and minds together by empowering the life sciences industry to support local communities

ZURICH, Switzerland, April 19, 2024 (GLOBE NEWSWIRE) -- Today, Life Science Cares, a collective effort of the life science industry to reduce the impact of poverty and inequality in their communities, launched in Switzerland, marking its first expansion as an independent association into geographies outside of the United States.

“We are excited to launch Life Science Cares Switzerland (LSCS) today, in time, to engage with the local community at the upcoming Swiss Biotech Day in Basel,” said Nadine Zahnd, Managing Director of LSCS. “At the heart of our life sciences community is the overwhelming sense to act and do good. We are building bridges between Swiss Life Science Organizations and local charitable organizations for individuals who may otherwise fail to access the opportunities afforded to so many of us.”

In Switzerland in 2021, 1.24 million people, including many families are considered at the brink of poverty. Those affected are at risk of losing their social contacts and often suffer from psychological and physical health problems. Children in such families face often insurmountable obstacle to reach their full potential. It is the mission of LSCS to break this cycle and offer a path to unlock opportunity.

At the Swiss Biotech Day, LSCS will be showcased in the Plenary Session on 22 April 2024 and in a dedicated Panel discussion featuring the Swiss Red Cross, Cooley LLP, Novartis, the Swiss Biotech Association (SBA) and Molecular Partners at 4.30 pm at Marriott Hotel in Basel. Information will be available for everyone who wishes to contribute to our mission at the SBA Booth.

The Board of LSCS will be constituted by Isabel Dalli, Novartis; Sarah MacDonald, CEO LSC, Inc.; Dorothea Bergler, Swiss Red Cross; Patrick Amstutz, Swiss Biotech Association / Molecular Partners; Dieter Gericke, Homburger; Christoph Schmidt, up&up communication.

Founding Members include Ulf Grawunder, Founder and former CEO of NBE Therapeutics; Bill Burns, former CEO of Roche Pharmaceuticals; Dominik Höchli, former Head of Global Medical Affairs at Abbvie; Patrick Amstutz, CEO of Molecular Partners and Chairman of Swiss Biotech Association, as well as Molecular Partners, OM Pharma, the Swiss Biotech Association, HBM Healthcare Investments and others.

About Life Science Cares Switzerland:

Life Science Cares Switzerland brings together the life science community and local non-profit organizations to build bridges for people with limited opportunities in our country. Our goal is to provide access to education and opportunity for all who wish to develop beyond their own limitations – by connecting the talents and minds of the life science community with the hearts of non-profit organizations. Learn more at

Contact:

Life Science Cares Switzerland

Nadine Zahnd-Straumann

Scheuchzerstrasse 35

CH-8006 Zürich



EN
19/04/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Molecular Partners

 PRESS RELEASE

Molecular Partners Announces Presentation of First Imaging and Dosimet...

Molecular Partners Announces Presentation of First Imaging and Dosimetry Data of DLL3-Targeting Radiotherapy MP0712 in Patients at TWC 2026 Specific tumor accumulation and attractive biodistribution highly supportive of MP0712 clinical development for treatment of DLL3-expressing cancersDosimetry data highlight Radio-DARPins as vector for precise delivery of potent alpha-emitting isotopes to tumorsMP0712 Phase 1/2a study open in U.S. with initial clinical data expected in 2026Molecular Partners to host conference call February 2 at 8AM ET (2PM CET), joined by renowned nuclear medicine exper...

 PRESS RELEASE

Molecular Partners Highlights Clinical Development Progress and Antici...

Molecular Partners Highlights Clinical Development Progress and Anticipated Milestones at 44th Annual J.P. Morgan Healthcare Conference Phase 1/2a study with lead Radio-DARPin MP0712 initiated; first patient dosing expected Q1 2026, initial data anticipated in 2026Full imaging and dosimetry data from MP0712 compassionate care program to be presented at TWC 2026Phase 2 investigator-initiated trial of MP0317 now open with patient dosing ongoing, exploring MP0317 in combination with standard-of-care for patients with cholangiocarcinomaPhase 1/2a trial of multi-specific T cell engager MP0533 on...

 PRESS RELEASE

Molecular Partners to Present at 44th Annual J.P. Morgan Healthcare Co...

Molecular Partners to Present at 44th Annual J.P. Morgan Healthcare Conference ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced it will present the Company’s latest developments and outlook for 2025 at the 44th Annual J.P. Morgan Healthcare Conference, taking place January 12-15 in San Francisco, CA, USA. Chief Executive Officer Patrick Amstutz will pres...

 PRESS RELEASE

Molecular Partners Forms Scientific Advisory Board to Accelerate Devel...

Molecular Partners Forms Scientific Advisory Board to Accelerate Development of Targeted Radiotherapeutics Chaired by globally renowned nuclear medicine expert Prof. Ken Herrmann, M.D. Other Board members James Cook, Jason Lewis, Ph.D., and Michael Morris, M.D. bring significant clinical and industry expertise, supporting transition from early clinical validation to strategic development ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drug...

 PRESS RELEASE

Molecular Partners Presents Updated Data from Ongoing Phase 1/2a Trial...

Molecular Partners Presents Updated Data from Ongoing Phase 1/2a Trial of MP0533 in AML at ASH Annual Meeting Poster outlines clinical benefit with acceptable safety profile across 9 tested dosing regimensAccelerated step-up dosing and higher dosing frequency is feasible and results in increased exposure Six of eight responders presented with low bone marrow blast counts at baseline, supporting further investigation in this patient population most likely to benefit from MP0533 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch